Five-year partnership aims to revolutionize pharmaceutical research with continuous AI-assisted experimentation
Technology giant Nvidia and pharmaceutical company Eli Lilly have announced plans to invest up to one billion dollars over the next five years to establish an AI-powered research laboratory dedicated to discovering and developing new medications.
The new facility will be located in California’s San Francisco Bay Area, with operations set to begin this year. The laboratory will utilize Nvidia’s recently announced next-generation AI processors, Nvidia Vera Rubin, marking a significant step forward in applying artificial intelligence to pharmaceutical research.
Combining Scientific Expertise with AI Innovation
The laboratory will bring together Eli Lilly specialists in biology, chemistry, and medicine with Nvidia’s AI engineers and model developers. These teams will collaborate to generate large datasets and develop advanced AI models designed to accelerate the drug discovery process.
At the heart of the collaboration will be Nvidia BioNeMo, a platform specifically designed to speed up drug discovery and development processes. According to both companies, the primary objective is creating a “continuous learning system” that enables non-stop AI-assisted experimentation. This approach could significantly reduce the time required to bring new treatments to market.
Transforming an Industry
“AI is transforming every industry, and its most profound impact will be in science,” said Nvidia’s chief executive. Eli Lilly’s CEO echoed this sentiment, emphasizing that combining the company’s vast data volumes and scientific expertise with Nvidia’s computing power “could reinvent drug discovery.”
Beyond pharmaceutical research, the partnership will explore AI applications in clinical development, manufacturing, and supply chains, including through robotics, multimodal models, and digital twins. However, neither Nvidia nor Lilly provided specific details regarding the funding arrangement.
Part of a Broader AI Strategy
The announcement was made at the opening of the JPMorgan Healthcare Conference in San Francisco and comes just months after Eli Lilly revealed it is building its own supercomputer based on more than a thousand Nvidia Grace Blackwell AI chips.
Eli Lilly joins a growing number of pharmaceutical companies increasingly relying on sophisticated artificial intelligence models to research and discover new treatments, aiming to reduce the time needed to bring new products to market.
The pharmaceutical industry has long grappled with lengthy development timelines and high costs associated with bringing new drugs from concept to market. This process typically takes over a decade and costs billions of dollars. By leveraging AI’s ability to analyze vast amounts of biological and chemical data, identify patterns, and predict outcomes, companies like Eli Lilly hope to streamline this process dramatically.
This partnership represents one of the most significant investments in AI-driven pharmaceutical research to date, signaling a new era in drug discovery where artificial intelligence plays a central role in addressing humanity’s most pressing health challenges.
